Complaint
Product Name | Retatrutide |
Cas | 2381089-83-2 |
Analysis | HPLC |
Storage | Keep in a cool and dry place, well-closed, away from moisture or direct sunlight. |
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.[1] It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial
Our company has established a US warehouse. Once consumers place an order, they can receive the goods within 48 hours without high shipping costs.
| Semaglutide | Vial package | 5mg 10mg 15mg |
| Tirzepatide | Vial package | 5mg 10mg 15mg |
| Retatrutide | Vial package | 5mg 10mg 15mg |
